976 related articles for article (PubMed ID: 32433340)
1. Use of antidepressants with pharmacogenetic prescribing guidelines in a 10-year depression cohort of adult primary care patients.
Jessel CD; Mostafa S; Potiriadis M; Everall IP; Gunn JM; Bousman CA
Pharmacogenet Genomics; 2020 Sep; 30(7):145-152. PubMed ID: 32433340
[TBL] [Abstract][Full Text] [Related]
2. Influence of CYP2D6 and CYP2C19 gene variants on antidepressant response in obsessive-compulsive disorder.
Brandl EJ; Tiwari AK; Zhou X; Deluce J; Kennedy JL; Müller DJ; Richter MA
Pharmacogenomics J; 2014 Apr; 14(2):176-81. PubMed ID: 23545896
[TBL] [Abstract][Full Text] [Related]
3. The Influence of CYP2D6 and CYP2C19 Genetic Variation on Diabetes Mellitus Risk in People Taking Antidepressants and Antipsychotics.
Austin-Zimmerman I; Wronska M; Wang B; Irizar H; Thygesen JH; Bhat A; Denaxas S; Fatemifar G; Finan C; Harju-Seppänen J; Giannakopoulou O; Kuchenbaecker K; Zartaloudi E; McQuillin A; Bramon E
Genes (Basel); 2021 Nov; 12(11):. PubMed ID: 34828364
[TBL] [Abstract][Full Text] [Related]
4. Antidepressant pharmacogenetics in children and young adults: A systematic review.
Maruf AA; Greenslade A; Arnold PD; Bousman C
J Affect Disord; 2019 Jul; 254():98-108. PubMed ID: 31112844
[TBL] [Abstract][Full Text] [Related]
5. Association of CYP2C19 and CYP2D6 Poor and Intermediate Metabolizer Status With Antidepressant and Antipsychotic Exposure: A Systematic Review and Meta-analysis.
Milosavljevic F; Bukvic N; Pavlovic Z; Miljevic C; Pešic V; Molden E; Ingelman-Sundberg M; Leucht S; Jukic MM
JAMA Psychiatry; 2021 Mar; 78(3):270-280. PubMed ID: 33237321
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenetic testing among patients with depression in a US managed care population.
Anderson HD; Thant TM; Kao DP; Crooks KR; Mendola ND; Aquilante CL
Clin Transl Sci; 2022 Jul; 15(7):1644-1653. PubMed ID: 35385214
[TBL] [Abstract][Full Text] [Related]
7. Clinical validity: Combinatorial pharmacogenomics predicts antidepressant responses and healthcare utilizations better than single gene phenotypes.
Altar CA; Carhart JM; Allen JD; Hall-Flavin DK; Dechairo BM; Winner JG
Pharmacogenomics J; 2015 Oct; 15(5):443-51. PubMed ID: 25686762
[TBL] [Abstract][Full Text] [Related]
8. Prescribing Prevalence of Medications With Potential Genotype-Guided Dosing in Pediatric Patients.
Ramsey LB; Ong HH; Schildcrout JS; Shi Y; Tang LA; Hicks JK; El Rouby N; Cavallari LH; Tuteja S; Aquilante CL; Beitelshees AL; Lemkin DL; Blake KV; Williams H; Cimino JJ; Davis BH; Limdi NA; Empey PE; Horvat CM; Kao DP; Lipori GP; Rosenman MB; Skaar TC; Teal E; Winterstein AG; Owusu Obeng A; Salyakina D; Gupta A; Gruber J; McCafferty-Fernandez J; Bishop JR; Rivers Z; Benner A; Tamraz B; Long-Boyle J; Peterson JF; Van Driest SL;
JAMA Netw Open; 2020 Dec; 3(12):e2029411. PubMed ID: 33315113
[TBL] [Abstract][Full Text] [Related]
9. Does obtaining CYP2D6 and CYP2C19 pharmacogenetic testing predict antidepressant response or adverse drug reactions?
Solomon HV; Cates KW; Li KJ
Psychiatry Res; 2019 Jan; 271():604-613. PubMed ID: 30554109
[TBL] [Abstract][Full Text] [Related]
10. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2C19 and CYP2D6 and SSRIs.
Brouwer JMJL; Nijenhuis M; Soree B; Guchelaar HJ; Swen JJ; van Schaik RHN; Weide JV; Rongen GAPJM; Buunk AM; de Boer-Veger NJ; Houwink EJF; van Westrhenen R; Wilffert B; Deneer VHM; Mulder H
Eur J Hum Genet; 2022 Oct; 30(10):1114-1120. PubMed ID: 34782755
[TBL] [Abstract][Full Text] [Related]
11. Seizures and myoclonus associated with antidepressant treatment: assessment of potential risk factors, including CYP2D6 and CYP2C19 polymorphisms, and treatment with CYP2D6 inhibitors.
Spigset O; Hedenmalm K; Dahl ML; Wiholm BE; Dahlqvist R
Acta Psychiatr Scand; 1997 Nov; 96(5):379-84. PubMed ID: 9395157
[TBL] [Abstract][Full Text] [Related]
12. Protocol for a pharmacogenetic study of antidepressants: characterization of drug-metabolizing profiles of cytochromes CYP2D6 and CYP2C19 in a Sardinian population of patients with major depressive disorder.
Pinna M; Manchia M; Pisanu C; Pinna F; Paribello P; Carta A; Meloni A; Conversano C; Del Zompo M; Mola F; Squassina A; Carpiniello B
Psychiatr Genet; 2021 Oct; 31(5):186-193. PubMed ID: 34282075
[TBL] [Abstract][Full Text] [Related]
13. Exploring the role of drug-metabolising enzymes in antidepressant side effects.
Hodgson K; Tansey KE; Uher R; Dernovšek MZ; Mors O; Hauser J; Souery D; Maier W; Henigsberg N; Rietschel M; Placentino A; Craig IW; Aitchison KJ; Farmer AE; Dobson RJ; McGuffin P
Psychopharmacology (Berl); 2015 Jul; 232(14):2609-17. PubMed ID: 25761838
[TBL] [Abstract][Full Text] [Related]
14. Genetic testing for CYP2D6 and CYP2C19 suggests improved outcome for antidepressant and antipsychotic medication.
Walden LM; Brandl EJ; Tiwari AK; Cheema S; Freeman N; Braganza N; Kennedy JL; Müller DJ
Psychiatry Res; 2019 Sep; 279():111-115. PubMed ID: 29699889
[TBL] [Abstract][Full Text] [Related]
15. Rationale and design for a pragmatic randomized trial to assess gene-based prescribing for SSRIs in the treatment of depression.
Hines LJ; Wilke RA; Myers R; Mathews CA; Liu M; Baye JF; Petry N; Cicali EJ; Duong BQ; Elwood E; Hulvershorn L; Nguyen K; Ramos M; Sadeghpour A; Wu RR; Williamson L; Wiisanen K; Voora D; Singh R; Blake KV; Murrough JW; Volpi S; Ginsburg GS; Horowitz CR; Orlando L; Chakraborty H; Dexter P; Johnson JA; Skaar TC; Cavallari LH; Van Driest SL; Peterson JF;
Clin Transl Sci; 2024 Jun; 17(6):e13822. PubMed ID: 38860639
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenomic testing for CYP2C19 and CYP2D6 in cyclic vomiting syndrome.
Patel M; Partovi O; Karrento K; Garacchi Z; Balasubramanian G; Venkatesan T
Neurogastroenterol Motil; 2024 Jan; 36(1):e14705. PubMed ID: 37953495
[TBL] [Abstract][Full Text] [Related]
17. Association of CYP2D6 and CYP2C19 metabolizer status with switching and discontinuing antidepressant drugs: an exploratory study.
Brouwer JMJL; Wardenaar KJ; Nolte IM; Liemburg EJ; Bet PM; Snieder H; Mulder H; Cath DC; Penninx BWJH
BMC Psychiatry; 2024 May; 24(1):394. PubMed ID: 38797832
[TBL] [Abstract][Full Text] [Related]
18. Frequencies of
Scherf-Clavel M; Weber H; Unterecker S; Müller DJ; Deckert J
World J Biol Psychiatry; 2024 Apr; 25(4):214-221. PubMed ID: 38493365
[TBL] [Abstract][Full Text] [Related]
19. Should a routine genotyping of CYP2D6 and CYP2C19 genetic polymorphisms be recommended to predict venlafaxine efficacy in depressed patients treated in psychiatric settings?
Taranu A; Colle R; Gressier F; El Asmar K; Becquemont L; Corruble E; Verstuyft C
Pharmacogenomics; 2017 May; 18(7):639-650. PubMed ID: 28480819
[TBL] [Abstract][Full Text] [Related]
20. Serum clomipramine and desmethylclomipramine levels in a CYP2C19 and CYP2D6 intermediate metabolizer.
Brown JT; Schneiderhan M; Eum S; Bishop JR
Pharmacogenomics; 2017 May; 18(7):601-605. PubMed ID: 28470111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
